[Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
CONCLUSION: The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed.
PMID: 31612261 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | ENT & OMF | Head and Neck Cancer | HNSCC | Immunotherapy | Nutrition | Skin Cancer | Squamous Cell Carcinoma | Study